Vitruvias Recalls Thyroid Tablets Over Potency Concerns

Vitruvias Therapeutics has initiated a nationwide recall of a specific lot of thyroid medication after testing confirmed the tablets may contain more active hormone than labeled, posing a risk of hyperthyroidism to patients. The recall, announced by the company on August 21, 2026, and published by the FDA on August 24, affects lot number 504950 of Thyroid Tablets, USP 30 mg. Of the 3,655 units released from this lot, 1,955 were sold and distributed to direct accounts across the country between January 31, 2025, and September 30, 2025. The product has an expiration date of September 30, 2026, meaning affected bottles may still be in use.

The recall is unusual because it involves a superpotent product rather than a subpotent one. Thyroid USP is a natural preparation derived from porcine thyroid glands, prescribed for hypothyroidism. An overly potent dose can lead to hyperthyroidism, or an overactive thyroid. Symptoms can include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and abnormal heart rhythms. Vitruvias Therapeutics stated it has not received any reports of adverse health events related to this...